That's a really important question. The newly FDA-approved combination of acalabrutinib (Calquence) and venetoclax (Venclexta) was specifically studied and approved as a first-line treatment — meaning for people who haven't been treated before.
If acalabrutinib has already been taken for a few years, this particular Show Full Answer
That's a really important question. The newly FDA-approved combination of acalabrutinib (Calquence) and venetoclax (Venclexta) was specifically studied and approved as a first-line treatment — meaning for people who haven't been treated before.
If acalabrutinib has already been taken for a few years, this particular combination may not apply in the same way, since the approval is based on trials with treatment-naive patients. However, this doesn't mean there are no options. There are other treatments available for CLL that has been previously treated, including:
- Venetoclax on its own or in other combinations
- Ibrutinib (Imbruvica) or newer BTK inhibitors like pirtobrutinib
- Rituximab-based combinations
- PI3K inhibitors like idelalisib
The best next step is to have an open conversation with a healthcare provider about what treatment path makes the most sense given the history with acalabrutinib. Every situation is different, and a care team can help figure out the right fit.
June 4
Join
Your Privacy Choices
